# Racotumomab

Source: https://onco.cc/drugs/racotumomab/  
OnCo record `racotumomab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Racotumomab (Vaxira) is a Cuban vaccine for advanced non-small cell lung cancer, given after first-line treatment to patients whose cancer has responded or held steady. In a placebo-controlled trial of 176 patients it lengthened median survival from 6.8 to 8.2 months. It is registered in Cuba and is not approved in the United States or the European Union.

## Summary

Racotumomab is an anti-idiotype vaccine targeting the tumour-associated ganglioside NeuGcGM3, formulated with aluminium hydroxide (racotumomab-alum) and made by the Centro de Inmunología Molecular in Havana, which holds its registration. Cuba's regulator CECMED lists Vaxira under registration number B-25-015-L03, with an inscription date of 26 May 2025, for patients with advanced (stage IIIB or IV) non-small cell lung cancer who have an objective response or stable disease after first-line treatment, as switch maintenance. OnCo has not read whether there was an earlier Cuban registration, so no earlier date is given.

In a randomised, multicentre, placebo-controlled trial, 176 patients with stage IIIB or IV disease and at least stable disease after first-line chemotherapy received racotumomab-alum (87) or placebo (89). Median overall survival was 8.23 against 6.80 months (hazard ratio 0.63, 95% CI 0.46 to 0.87, P = 0.004) and median progression-free survival 5.33 against 3.90 months (hazard ratio 0.73, 95% CI 0.53 to 0.99, P = 0.039). The authors called the trial a preliminary estimate of efficacy; only five patients in each group had further anticancer treatment at progression, which is far from current practice elsewhere.

## Fields

- Kind: Treatment
- Status: established
- Last checked: 2026-11-16
- Also known as: Racotumomab-alum
- Tags: cuba; cancer-vaccine
- Brand: Vaxira
- Modality: Therapeutic cancer vaccine: anti-idiotype monoclonal antibody adsorbed on aluminium hydroxide, intradermal
- Mechanism: An anti-idiotype antibody that mimics NeuGcGM3, a ganglioside found on tumour cells, so that the patient's immune system makes antibodies against the ganglioside itself.
- Approvals: Cuba (CECMED) 2025: Advanced (stage IIIB or IV) non-small cell lung cancer with an objective response or stable disease after first-line treatment (switch maintenance)
- Dosing: Intradermal; Five doses of 1 mg 14 days apart, then every 28 days; each dose is four 0.25 mL injections at different sites (CECMED summary of product characteristics, text of 12 May 2025)

## Notes

- Not approved by the FDA or the EMA. Registrations in other countries are reported in the press and were not read from a regulator's own page, so none is listed.

## Sources

- CECMED: registration entry and summary of product characteristics for Vaxira (racotumomab) (in Spanish): https://www.cecmed.cu/registro/rcp/biologicos/vaxirar-racotumomab
- Alfonso et al., randomised trial of racotumomab-alum in advanced NSCLC (Clin Cancer Res 2014): https://doi.org/10.1158/1078-0432.CCR-13-1674

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- companies: [CIMAB](https://onco.cc/companies/cimab/)
- institutions: [Center for State Control of Medicines, Equipment and Medical Devices (CECMED)](https://onco.cc/institutions/cecmed/)
- key papers: [Racotumomab-alum vaccine as switch maintenance in advanced non-small cell lung cancer: a randomised placebo-controlled trial](https://onco.cc/key-papers/paper-alfonso-racotumomab-maintenance-nsclc-ccr-2014/)

---
JSON: https://onco.cc/api/v1/entities/racotumomab.json